natgillin/translations-raw huggingface dataset:
atgādina šajā jautājumā augsti vērtējamo Arābu valstu miera iniciatīvas ieguldījumu, kas ir patiesa iespēja ieviest ilgstošu un vispārēju mieru šajā reģionā; aicina arābu valstis aktīvi piedalīties pašreizējā konflikta un krīzes atrisināšanā; aicina Izraēlas valdību izmantot izdevību, ko sniedz šī iniciatīva; tomēr uzsver, ja šī iespēja pēc iespējas drīzāk netiks izmantota, tā varētu zust pavisam, kam būtu dramatiskas sekas attiecībā uz reģiona iedzīvotājiem;
Recalls in this context the valuable contribution of the Arab Peace Initiative, which constitutes a genuine opportunity for comprehensive and lasting peace in the region; invites the Arab countries to play an active role in resolving the current crisis and conflict; invites the Israeli Government to recognise the window of opportunity offered by this initiative; insists nevertheless that this opportunity, if not urgently seized, could be missed entirely, with tragic consequences for all the peoples of the region;
ir gandarīts par žurnālista Alan Johnston atbrīvošanu;
Welcomes the freeing of the journalist Alan Johnston;
pieprasa tūlītēju trīs Izraēlas karavīru atbrīvošanu;
Calls for the three Israeli soldiers to be freed immediately;
prasa Eiropas Savienības dalībvalstīm atjaunot patiesu dialogu ar Sīriju, lai panāktu vispārēju konfliktu noregulēšanu un nodrošinātu stabilitāti reģionā;
Calls on the Member States of the European Union to reestablish a genuine dialogue with Syria aimed at achieving a comprehensive settlement of the conflict and guaranteeing regional stability;
pauž bažas par politiskās šķelšanās pastiprināšanās risku un tās sekām Lībijā, kā arī par mieru un stabilitāti reģionā, aicina visas iesaistītās puses atrisināt Libānas iekšējo politisko krīzi, izmantojot dialogu;
Expresses its concern at the danger of increased political divisions in Lebanon and the consequences of this and for peace and stability in the region and calls on all the parties concerned in Lebanon to solve the internal political crisis through dialogue;
nosoda 24. jūnijā notikušo uzbrukumu, kura rezultātā gāja bojā seši ANO miera uzturēšanas spēku kareivji;
Condemns the attack which led to the deaths of 6 soldiers from the UN peacekeeping force on 24 June this year;
uzsver, ka tikai karaspēka izvēršana ANO vadībā Libānas dienvidos bez politiska procesa, nevar uz ilgu laiku atrisināt krīzi un pakļauj lielam riskam ANO pagaidu spēkus Libānā; aicina Padomi iesniegt Parlamentā politisko stratēģiju un politisko iniciatīvu, ko tā domā uzsākt, lai rastu ilgstošu risinājumu problēmai; prasa, lai Augstais pārstāvis kopējas ārpolitikas un drošības politikas jautājumos visdrīzākajā laikā iesniedz Parlamentam ziņojumu par šo jautājumu;
Stresses that simply deploying troops under the aegis of the UN in South Lebanon cannot, in the absence of a political process, provide a long-term solution to the crisis and exposes FINUL to serious risk; calls on the Council to present to Parliament its political strategy and the political initiatives it intends to undertake in order to find a lasting solution to the problem; asks that the High Representative for the Common Foreign and Security Policy consult Parliament as soon as possible on this issue;
nosoda Fatah Al-Islam uzbrukumus un iefiltrēšanos bēgļu nometnēs, kas palestīniešu bēgļus padarījuši par galvenajiem sadursmju upuriem; uzsver, ka šī ārkārtas situācija no jauna parāda, ka jāpanāk taisnīgs un vispārējs palestīniešu bēgļu jautājuma atrisinājums, pamatojoties uz ANO rezolūciju Nr. 194;
Condemns the attacks and actions undertaken by Fatah Al-Islam and its infiltration of the refugee camps, as a result of which the Palestinian refugees have become the main victims of the clashes; stresses that the emergency situation once again highlights the need to bring about a fair, global settlement for the Palestinian refugees on the basis of United Nations Resolution 194;
uzdod priekšsēdētājam nosūtīt šo rezolūciju Padomei, Komisijai, Izraēlas, Libānas un Sīrijas parlamentiem un valdībām, Palestīniešu pašpārvaldei, Arābu valstu līgas ģenerālsekretāram, Krievijai un ASV, kā arī ANO ģenerālsekretāram.
Instructs its President to forward this resolution to the Council, the Commission, the parliaments and governments of Israel, Lebanon and Syria, the Palestinian National Authority, the Secretary-General of the Arab League, Russia, the United States of America, and the Secretary-General of the United Nations.
iesniedza Vittorio Agnoletto, Helmuth Markov un Jens Holm
by Vittorio Agnoletto, Helmuth Markov and Jens Holm
Eiropas Parlamenta rezolūcija par TRIPS līgumu un medikamentu pieejamību
European Parliament resolution on the TRIPS Agreement and access to medicines
ņemot vērā 2007. gada 20. jūnija rezolūciju par Tūkstošgades attīstības mērķiem – pusceļš Pieņemtie teksti, P6_TA(2007)0274 . , 2007. gada 23. maija rezolūciju par ekonomikas partnerattiecību nolīgumiem Pieņemtie teksti, P6_TA(2007)0224 . un 2006. gada 6. jūlija rezolūciju „HIV/AIDS – laiks rīkoties” Pieņemtie teksti, P6_TA(2006)0321 . un 2006. gada 30 novembra rezolūciju par AIDS Pieņemtie teksti, P6_TA(2006)0526 . ,
having regard to its resolutions of 20 June 2007 on the Millennium Development Goals – the midway point Texts Adopted, P6_TA(2007)0274 . , of 23 May 2007 on Economic Partnership Agreements Texts Adopted, P6_TA(2007)0204 . , of 6 July 2006 on HIV/AIDS: Time to Deliver Texts Adopted, P6_TA(2006)0321 . , and of 30 November 2006 on AIDS Texts Adopted, P6_TA(2006)0526 . ,
tā kā vairāk nekā 95 % no 39,5 miljoniem HIV/AIDS slimnieku dzīvo jaunattīstības valstīs, galvenokārt Āfrikā; tā kā pasaulē ir aptuveni 15 miljoni bāreņu, kas par tādiem ir kļuvuši HIV/AIDS dēļ, un no tiem 12,3 miljoni dzīvo Aizsahāras Āfrikā;
whereas over 95% of the 39.5 million people in the world suffering from HIV/AIDS live in developing countries, mostly in Africa; whereas there are an estimated 15 million HIV/AIDS orphans globally, 12.3 million of them living in Sub-Saharan Africa,
tā kā tas ir pastāvīgs smags cilvēktiesību pārkāpums, ko var salīdzināt ar pastāvīgu genocīdu;
whereas this is a permanent massive human rights violation comparable to a planned permanent genocide,
tā kā piecus gadus pēc tam, kad pieņēma Dohas deklarāciju, kurā noteikts, ka “katrai PTO dalībvalstij ir tiesības piešķirt piespiedu licences un katra PTO dalībvalsts drīkst noteikt iemeslus, dēļ kuriem tiek piešķirtas šīs licences”, PTO brīdina, ka joprojām pastāv 74 % AIDS medikamentu monopols un 77 % Āfrikas iedzīvotāju nav pieejama AIDS ārstēšana;
whereas, five years after the Doha Declaration, which stated that 'each member state of the WTO has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted', the WHO is warning that 74% of AIDS medicines are still under monopoly and 77% of Africans still have no access to AIDS treatment,
tā kā pēc Dohas deklarācijas pieņemšanas nav izdevies piemērot mehānismu, kas paredzēts , lai nodrošinātu medikamentu pieejamību, jo līdz šim PTO nav saņēmusi nevienu paziņojumu ne no vienas obligāto medikamentu eksportētājas valsts vai importētājas valsts;
whereas the application of the mechanism designed to give access to medicines after the adoption of the Doha Declaration has been a complete failure, as the WTO has so far received no notification from any exporting or importing country of compulsory medicines,
tā kā procedūras noteikumi un pamatprasības, kas reglamentē obligāto licenču izdošanu importētājai valstij (piemērotos gadījumos) un eksportētājai valstij, kā arī ar licencēšanu saistītie nosacījumi un paziņojumi, ir galvenie iespējamie šķēršļi PTO lēmuma efektīvai izmantošanai;
whereas the procedural and substantive requirements that govern the issuance of compulsory licences by importing (where applicable) and exporting countries, as well as the conditions and notifications connected with that licensing, the political cost and the lack of incentive measures to accompany the use of the foreseen mechanism, constitute the principal potential obstacles to effective use of the WTO Decision,
lai gan tajā pašā laikā farmācijas nozares akciju turētāji un pārvaldītāji gūst lielu peļņu; tā kā lielākā daļa farmācijas nozares aizsargāto patentu ir ieviesti , izmantojot publiski finansētu pētniecību; tā kā lielākā daļa reģistrēto patentu, kuri ir nepieciešami, lai apkarotu plaši izplatītas epidēmijas dienvidu reģionos, ir atlīdzināti komerciālā veidā rūpnieciskajās valstīs;
whereas meanwhile the pharmaceutical industry's shareholders and management are enjoying their highest profits; whereas most patents which the industry defends have been established through public funded research; whereas most registered patents that are necessary to fight major epidemics in the south have been largely reimbursed by their commercialisation in the industrialised countries;
tā kā PTO lēmuma īstenošanas regulā nav pievērsta pietiekama uzmanību jautājumam par tehnoloģijas nodošanu un resursu palielināšanu, 13. apsvērumā vienkārši pārfrāzējot PTO lēmuma vispārējo tekstu;
whereas the WTO Decision's implementing Regulation pays scant attention to issues of technology transfer and capacity-building, merely paraphrasing at recital 13 some general language of the WTO Decision,
whereas through the EPA negotiations and other bilateral or regional FTAs, the European Union is seeking to include new intellectual property WTO+ obligations on ACP and other poor developing countries and LDCs that could affect their public health programmes,
whereas through the EPA negotiations and other bilateral or regional FTAs, the European Union is seeking to include new intellectual property WTO+ obligations on ACP and other poor developing countries and LDCs that could affect their public health programmes,
tā kā ES pārrunā Līguma par sadarbību patentu jomā ( PCT ) un Patentu tiesību līguma ( PLT ) saistību stingru ievērošanu vai pieņemšanu ierosinātajos ekonomikas partnerattiecību nolīgumos ( EPA ) ar Āfrikas, Karību jūras reģiona un Klusā okeāna valstīm ; whereas the EU also sets conditions to the way that parties can determine their exhaustion regime, which will harm parallel importations although they are a flexibility allowed by the TRIPS Agreement,
whereas, in its proposed Economic Partnership Agreements (EPAs) with the African, Caribbean and Pacific (ACP) countries, the EU is negotiating for adherence to or acceptance of the obligations of the Patent Cooperation Treaty (PCT) and the Patent Law Treaty (PLT), and for the incorporation of the terms of Directive 2004/48/EC on the enforcement of intellectual property rights; whereas the EU also sets conditions to the way that parties can determine their exhaustion regime, which will harm parallel importations although they are a flexibility allowed by the TRIPS Agreement,
whereas the WHO decided to set up an Intergovernmental Working Group on Public Health, Innovation and Intellectual property (IGWG) in which the EU Member States and the Commission are actively participating, in order to draw, by May 2008, a strategy and global action plan on access to medicines and TRIPS issues,
whereas the WHO decided to set up an Intergovernmental Working Group on Public Health, Innovation and Intellectual property (IGWG) in which the EU Member States and the Commission are actively participating, in order to draw, by May 2008, a strategy and global action plan on access to medicines and TRIPS issues,
pauž visnopietnākās bažas par HIV/AIDS un citu epidēmiju izplatību pasaules nabadzīgāko iedzīvotāju vidū un par nepietiekamo koncentrēšanos uz HIV/AIDS profilaksi, galveno medikamentu nepieejamību, nepietiekamu finansējumu un pētījumu trūkumu galveno epidēmiju jomā;
Expresses its deepest concern at the spread of HIV/AIDS and other epidemics among the poorest peoples in the world and at the lack of focus on the prevention of HIV/AIDS, the inaccessibility of key medicines, the insufficiency of funding and the continuing need for more research into the major epidemics;
Strongly welcomes the decisions taken by Brazil and Thailand to grant compulsory licences for the production of medicines, using the flexibilities existing in Article 31 of the TRIPS Agreement; asks the Commission and the Council to also publicly support the use of this mechanism by those countries, and to encourage other developing countries to take similar steps;
Strongly welcomes the decisions taken by Brazil and Thailand to grant compulsory licences for the production of medicines, using the flexibilities existing in Article 31 of the TRIPS Agreement; asks the Commission and the Council to also publicly support the use of this mechanism by those countries, and to encourage other developing countries to take similar steps;
Considers that to simply make this provisional mechanism permanent on 30 August 2003 (Article 31A) will not help to resolve the problem of access to medicines, as no notification has been sent to the WTO so far;
Considers that to simply make this provisional mechanism permanent on 30 August 2003 (Article 31A) will not help to resolve the problem of access to medicines, as no notification has been sent to the WTO so far;
Calls on the Commission to take an initiative at the WTO in order to reduce the complexity of the mechanism, reduce the political costs of its use with clear political statements, and create economical incentive programmes in order to encourage its use;
Calls on the Commission to take an initiative at the WTO in order to reduce the complexity of the mechanism, reduce the political costs of its use with clear political statements, and create economical incentive programmes in order to encourage its use;
uzskata, ka ES politikas mērķim ir jābūt medikamentu pieejamībai par pieņemamu cenu jaunattīstības valstīs; calls on the Commission to consider the possibility of buying some patents of essential medicines, and to put them in the public sector;
Believes that the EU policy should aim at maximising the availability of pharmaceutical products at affordable prices in the developing world; calls on the Commission to consider the possibility of buying some patents of essential medicines, and to put them in the public sector;
Calls on the Commission to publicly support the immediate use of Article 30 of the TRIPS Agreement by all countries facing major epidemics and that experience difficulties in gaining access to the necessary medicines; aicina Padomi kopā ar Eiropas parlamentu pieņemt kopīgu paziņojumu par to, ka dalībvalstis savos valsts patenta tiesību aktos var brīvi izvēlēties piemērot TRIPS līguma 30. panta noteikumu par izņēmumu, lai atļautu medikamentu ražošanu un eksportu un lai risinātu sabiedrības veselības aizsardzības vajadzības importētājā valstī, un prasa Padomei un Komisijai, neveikt rīcību, kas kavē šādas darbības;
Calls on the Commission to publicly support the immediate use of Article 30 of the TRIPS Agreement by all countries facing major epidemics and that experience difficulties in gaining access to the necessary medicines; calls on the Council to adopt a Joint Policy Statement with Parliament to the effect that EU Member States remain free to use the Article 30 exception provision of the TRIPS Agreement under their domestic patent laws to authorise production and export 'with a view to addressing public health needs in importing Members' and asks the Council to mandate the Commission to refrain from taking action to interfere with these proceedings;
Calls on the Council to make it clear that the Commission has no mandate to negotiate pharmaceutical-related TRIPS-plus provisions affecting public health and access to medicines, of bilateral and regional agreements with developing countries;
Calls on the Council to make it clear that the Commission has no mandate to negotiate pharmaceutical-related TRIPS-plus provisions affecting public health and access to medicines, of bilateral and regional agreements with developing countries;
Calls on the Council to mandate the Commission to refrain from requesting adherence to or acceptance of the obligations of the Patent Cooperation treaty and the Patent Law Treaty, to refrain from incorporating the terms of Directive 2004/48/EC, not to introduce in the EPAs rules such as no original database protection, and not to include conditions which, by limiting ACP countries' choice of exhaustion regime, can reduce the scope of parallel imports;
Calls on the Council to mandate the Commission to refrain from requesting adherence to or acceptance of the obligations of the Patent Cooperation treaty and the Patent Law Treaty, to refrain from incorporating the terms of Directive 2004/48/EC, not to introduce in the EPAs rules such as no original database protection, and not to include conditions which, by limiting ACP countries' choice of exhaustion regime, can reduce the scope of parallel imports;
uzskata, ka tā vietā ES ir plašāk jāizmanto divpusējie nolīgumi un reģionālie nolīgumi, lai pieprasītu turpmākus īpašus nosacījumus, kas izveidotu sistēmu 2003. gada augusta lēmuma efektīvai īstenošanai un elastīguma mehānismu pilnīgai izmantošanai attiecībā uz sabiedrības veselības aizsardzību saskaņā ar TRIPS līgumu un Dohas deklarāciju;
Considers that the EU should instead proactively use all bilateral and regional agreements to require further specific provisions creating the framework for an effective implementation of the August 2003 Decision and for the use of the full flexibilities for public health under the TRIPS Agreement in compliance with the Doha Declaration;
uzsver, ka epidēmijas apkarošanai ir ļoti būtiski spēcīgi sabiedrības veselības aprūpes pakalpojumi, tostarp pētniecības iespējas, un iebilst pret nosacījumu piemērošanu, kuri izraisa to liberalizāciju;
Stresses that strong public health services, including research facilities, are essential in order to fight the epidemic, and opposes the situation of conditionality leading to their liberalisation;
aicina atbalstīt ģenerisko zāļu ražošanas nozaru attīstību slimību skartajos reģionos un valstīs, lai atvieglotu zāļu pieejamību par pieņemamu cenu;
Calls for support for the development of regional and national generic pharmaceutical-producing industries in affected areas with a view to facilitating access to affordable drugs;
prasa Padomei piešķirt konkrētu finansējuma daļu, lai modernizētu medikamentu ražošanas rūpnīcas, kas pieder vietējiem īpašniekiem jaunattīstības valstīs, vai celtu jaunas un palielināt ES kopējos ieguldījumus sabiedriskās pētniecības programmās un medikamentu izstrādē, kuri ir ļoti svarīgi jaunattīstības valstīm, kā arī garantēt, ka pētniecības iegūtie patenti ir publiski pieejami;
Asks the Council to commit to a specified level of funding to upgrade or construct pharmaceutical production facilities owned by local persons in developing countries and increase the EU aggregate funding to public research and development of medicines of special relevance to developing countries, and to guarantee that the patents resulting of such research remain public;
prasa Komisijai piešķirt finansējumu plaša mēroga pētniecības un attīstības darbam, lai pētītu slimības, kas saistītas ar nabadzību, tropu slimības un novārtā atstātas slimības, lai atbalstītu institūtus, kas vēlas sadarboties sabiedrības veselības aizsardzības iniciatīvās, kas paredzētas šādam darbam, un lai garantētu, ka no publiskā finansējuma līdzekļiem finansētu jaunu medikamentu pētniecības rezultāti netiks patentēti, bet ir publiski pieejami;
Asks the Commission to grant funding for R&D on poverty-related, tropical and neglected diseases across a broad spectrum of venues, to support research institutes willing to cooperate with public health initiatives dedicated to these efforts, and to guarantee that findings resulting of research on new medicines financed by public founding's will not be patented but will remain public;
prasa Padomei pilnvarot Komisiju aktīvi atbalstīt PVO Starpvaldību darba grupas darbu par sabiedrības veselību, jauninājumiem un intelektuālo īpašumu , kā piemēram priekšlikums, lai atkārtoti izpētīt saikni starp cenu veidošanos un pētniecības un attīstības izmaksām, lai izstrādātu jaunus darbojošos paraugus, un par šo darbu regulāri sniegt ziņojumus Parlamentam; prasa Padomei paredzēt iespēju Parlamentu oficiāli pārstāvēt Starpvaldību darba grupā, iekļaujot tajā dažus pārstāvjus;
Asks the Council to mandate the Commission to proactively support the work of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) at the WHO such as proposals that re-examine the link between pricing and the cost of R&D with a view to devising workable new models, and to report regularly to Parliament on its work; also asks the Council to envisage the possibility of having Parliament officially represented at the IGWG by some of its Members;
mudina farmaceitiskos uzņēmumus izstrādāt cenu alternatīvas, iekļaujot liela ražošanas apjoma un zemas cenas metodi, kas varētu uzlabot medikamentu pieejamību, nepieprasot obligātās licences;
Encourages pharmaceutical companies to pursue pricing alternatives involving a high-volume, low-margin approach, which could enhance access to medicines;
atgādina, ka medikamentu viltošana neattiecas uz patentu jautājumu;
Recalls that counterfeiting of medicines is not a patent issue as such;
uzdod priekšsēdētājam nosūtīt šo rezolūciju Padomei, Komisijai un ES dalībvalstu un ĀKK reģiona valstu valdībām, PTO un ANO Programmas cīņai pret HIV/AIDS, ANO Attīstības programmas un ANO Iedzīvotāju fonda vadītājiem.
Instructs its President to forward this resolution to the Council, the Commission, the governments of the EU Member States and ACP countries, the WTO and the heads of UNAIDS, UNDP and UNFPA.
Pamatojoties uz jautājumu, uz ko sniedz mutisku atbildi B6‑0134/2007 ,
further to Question for Oral Answer B6‑0134/2007
iesniedza Miroslav Ouzký , Georgs Andrejevs un John Bowis
by Miroslav Ouzký, Georgs Andrejevs and John Bowis
par rīcību sirds un asinsvadu slimību apkarošanai
on action to tackle cardiovascular disease
Eiropas Parlamenta rezolūcija par rīcību sirds un asinsvadu slimību apkarošanai
European Parliament resolution on action to tackle cardiovascular disease
ņemot vērā Nodarbinātības, sociālās politikas, veselības un patērētāju aizsardzības padomes 2004. gada 1.–2. jūnija sanāksmes secinājumus http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/lsa/80729.pdf ,
having regard to the conclusions of the Employment, Social Policy, Health and Consumer Affairs Council meeting on 1-2 June 2004 http://www.consilium.europa.eu/ueDocs/cms_Data/docs/pressData/en/lsa/80729.pdf ,
ņemot vērā Komisijas priekšlikumu sagatavot rīcības programmu sabiedrības veselības jomā 2007.–2013. gadam COM(2006) 234 galīgā redakcija. ,
having regard to the Commission Proposal for a Public Health Action Programme 2007-2013 COM(2006) 234 final ,
ņemot vērā Eiropas Parlamenta rezolūciju par Komisijas likumdošanas un darba programmu 2006. gadam, kurā ir uzsvērts, ka Komisijai „ pienācīgi jāīsteno paziņojumi par aptaukošanās, sirds slimību, diabēta, vēža, psihisko traucējumu un HIV/AIDS apkarošanu ” P6_TA(2005)0524 . ,
having regard to the European Parliament’s Resolution on the Commission legislative and work programme for 2006, which called on the Commission to ‘ensure a proper follow-up to its communications on the fight against obesity, heart diseases, diabetes, cancer, mental disorders and HIV/AIDS’ P6_TA(2005)0524 ,
ņemot vērā Pasaules Veselības organizācijas „Stratēģiju nelipīgo slimību profilaksei un apkarošanai Eiropā” EUR/RC56/R2. ,
having regard to the World Health Organisation’s ‘European Strategy for the Prevention and Control of Noncommunicable Diseases’ EUR/RC56/R2 ,
ņemot vērā ANO ceturtās Pasaules konferences par sievietēm Pekinas deklarācijas un rīcības platformas secinājumus un stratēģiskos mērķus attiecībā uz sievietēm un veselības jomu,
having regard to the conclusions and strategic objectives on women and health of the Beijing Declaration and Platform for Action, 4th UN World Conference on Women,
ņemot vērā Eiropas vadlīnijas sirds un asinsvadu slimību profilaksei Eur J Cardiovasc Prev Rehabil 2003 Dec;10(Suppl 1):S1-78. ,
having regard to the European Guidelines on cardiovascular disease prevention Eur J Cardiovasc Prev Rehabil 2003 Dec;10(Suppl 1):S1-78 ,